Eyes may be the window to the soul, but a person’s biological age could be reflected in their facial characteristics. Investigators from Mass General Brigham developed a deep learning algorithm called FaceAge that uses a photo of a person’s face to predict biological age and survival outcomes for patients withContinue Reading
According to the National Cancer Institute, a cancer biomarker is a “biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease such as cancer.” Biomarkers typically differentiate an affected patient from a person withoutContinue Reading
This post is co-written with Francisco Azuaje from Genomics England. Genomics England analyzes sequenced genomes for The National Health Service (NHS) in the United Kingdom, and then equips researchers to use data to advance biological research. As part of its goal to help people live longer, healthier lives, Genomics EnglandContinue Reading
Tonpor Kasa Kazia Therapeutics (NASDAQ:KZIA) stock soared 142% in morning trading Wednesday after the company reported positive Phase 2/3 results for its drug paxalisib in the treatment of glioblastoma. A primary analysis of the study, called GBM-AGILE, showed a median overall survival of 14.77 months for paxalisib treated patients versusContinue Reading
Ideaya Biosciences (NASDAQ:IDYA) shares jumped as much as 23% premarket on Monday after the oncology company reported positive interim data from an expansion dose cohort of a mid-stage trial of IDE397. IDE397 is a potential first-in-class MAT2A (methionine adenosyltransferase 2 alpha) inhibitor, that is being advanced as a monotherapy agentContinue Reading
Hailshadow Johnson & Johnson (NYSE:JNJ) announced Tuesday that its FDA-approved cell therapy Carvykti, developed with Legend Biotech (LEGN), outperformed standard of care in a Phase 3 trial for patients with a type of blood cancer called multiple myeloma. Citing interim data from its CARTITUDE-4 trial, the pharma giant said patientsContinue Reading
JHVEPhoto The U.S. Food and Drug Administration (FDA) has declined to approve an antibody-drug conjugate known as HER3-DXd developed by Merck (NYSE:MRK) and Daiichi Sankyo (OTCPK:DSKYF) as a late-line option for a certain type of lung cancer. The companies announced Thursday night that the agency issued a so-called complete responseContinue Reading
Anne Czichos Shares of Merck KGaA (OTCPK:MKGAF) (OTCPK:MKKGY) fell in European trading on Tuesday after the German drugmaker said it would discontinue a late-stage trial for its head and neck cancer therapy xevinapant as its early results indicated a potential failure. The decision comes after the study’s data monitoring committeeContinue Reading
jetcityimage/iStock Editorial via Getty Images AstraZeneca (NASDAQ:AZN) announced Tuesday that its blockbuster immunotherapy Imfinzi failed in a late-stage trial for patients with early-stage non-small cell lung cancer whose tumors have been surgically removed. Citing data from a Phase 3 trial called ADJUVANT BR.31, the company said Imfinzi did not demonstrateContinue Reading
jetcityimage/iStock Editorial via Getty Images Takeda (NYSE:TAK) has received EU regulatory approval for Fruzaqla for the treatment of patients with metastatic colorectal cancer who have been previously treatmed with standard therapies and who have progressed while on or are intolerant of treatment with trifluridine-tipiracil or regorafenib. The approval follows aContinue Reading
